• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LUAN Yali,WANG Yuanming,GAO Tiantian,WANG Xiaojun.Clinical application evaluation of cetuximab based on real-world data[J].Journal Of Pharmaceutical Research,2024,43(4):396-401[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2656times   Download 2268次 QR Code for this article
Scan with your phone!
基于真实世界数据的西妥昔单抗临床综合评价
栾亚丽1,王元明2,高田田1,王晓君1
Font:Larger+|Default|Smaller-
(1.山东第一医科大学附属省立医院药学部,山东 济南 250012;2.山东省药师协会,山东 济南 250101)
摘要:
目的 基于真实世界数据对西妥昔单抗开展临床综合评价,拟为临床合理使用及药品相关决策提供依据。方法 参考药品临床综合评价相关指南,基于真实世界数据,从安全性、有效性、经济性、创新性、适宜性、可及性6个维度对西妥昔单抗进行评价。结果 安全性,西妥昔单抗的多数不良反应与贝伐珠单抗、传统化疗方案无显著性差异,但皮疹发生率显著高于其他两种方案;有效性,西妥昔单抗与贝伐珠单抗无显著性差异,但5%的缓解率远低于临床试验结果;经济性,进行倾向值得分匹配后,应用西妥昔单抗与应用贝伐珠单抗方案的总费用无显著性差异,但显著高于传统化疗方案总费用;创新性,西妥昔单抗可用于头颈部鳞癌,填补了该领域临床治疗空白,满足了临床需求,具有一定的创新性;适宜性,非劣性;可及性,当前在山东地区的可获得性和可负担性相对较差。结论 与贝伐珠单抗相比较,西妥昔单抗在安全性、有效性、经济性、适宜性无显著性差异,创新性有优势,可及性略差。
关键词:  药品临床综合评价  结直肠癌  西妥昔单抗  真实世界数据
DOI:10.13506/j.cnki.jpr.2024.04.015
基金项目:山东省医学会临床药学应用研究项目(No.YXH2019ZX009);山东省第一批药品临床综合评价项目(No.2021YZ012)
Publication Date:April 25, 2024
Clinical application evaluation of cetuximab based on real-world data
LUAN Yali1,WANG Yuanming2,GAO Tiantian1,WANG Xiaojun1
(1.Department of Pharmacy, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan 250012, China; 2. Shandong Pharmacists Association, Jinan 250101, China)
Abstract:
Objective To conduct a clinical application evaluation of cetuximab based on real-world data, explore the content and methods of the clinical comprehensive evaluation of antitumor drugs, and provide a basis for rational clinical use and drug-related decision-making.Methods According to the guidelines of a clinical application evaluation, through real-world data, Cetuximab was evaluated in six dimensions.Results The evaluation results of various dimensions showed that most adverse reactions of cetuximab were not significantly different from bevacizumab and common chemotherapy regimens, but the incidence of rash was significantly higher than the others. In terms of efficacy,there is no significant difference between cetuximab and bevacizumab, but the remission rate of 5% is much lower than the clinical trial results. After propensity score matching, there was no significant difference in the total cost of the bevacizumab regimen, but it was significantly higher than the total cost of the common chemotherapy regimen. Cetuximab can be used for head and neck squamous cell carcinoma which can fill the clinical treatment gap and meet the clinical requirements. It is similar to other similar anti-tumor drugs and has no obvious advantages over the current suitability, but availability and affordability of cetuximab in Shandong is relatively poor. Conclusion Compared with bevacizumab, cetuximab has no significant difference in safety, efficacy, economy, and suitability, and has advantages in innovation and slightly poor accessibility.
Key words:  Clinical application evaluation  Colorectal cancer  Cetuximab  Real-world data
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.